{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228013","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-18T13:04:56+00:00","discovered_at":"2026-05-18T13:06:00.364805+00:00","generated_at":"2026-05-18T13:06:53.973603+00:00","sec_items":["1.01","2.03","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi","bullets":["Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.","Merger completed May 18, 2026; Soleno becomes wholly owned subsidiary; shares to be delisted from Nasdaq.","VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in Prader-Willi syndrome (ages 4+).","Entered $1.0B senior secured revolving credit facility (5-yr); initial $600M drawn; SOFR + 1.125%-1.75% margin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228013","json":"https://secwatch.observer/filing/0001193125-26-228013.json","markdown":"https://secwatch.observer/filing/0001193125-26-228013.md","text":"https://secwatch.observer/filing/0001193125-26-228013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:06:53.973603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"709977ce071e9f877b6dc826c190741c139178d2","claim":"NEUROCRINE BIOSCIENCES INC incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto at Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu maturing fifth anniversary of the Closing Date.","evidence_excerpt":"On May 14, 2026 (the “ Closing Date ”), the Company entered into a credit agreement (the “ Credit Agreement ”) with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (in such capacities, the “ Agent ”), and the lenders party thereto. The Credit Agreement provides for a five-year, $1.0 billion senior secured revolving credit facility (the “ Revolving Credit Facility ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$1.0 billion"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto"},{"label":"Rate","value":"Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu"},{"label":"Maturity","value":"fifth anniversary of the Closing Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"db7ac0d4a7eeff6071334b4f7e3c0990f65ca965","claim":"NEUROCRINE BIOSCIENCES INC completed an acquisition involving Soleno Therapeutics, Inc. for $53.00 per Soleno Share (closed 2026-05-18).","evidence_excerpt":"through Purchaser, commenced a tender offer to purchase all the outstanding shares of Soleno’s common stock, par value $0.001 per share (the “ Soleno Shares ”), at a price of $53.00 per Soleno Share (the “ Offer Price ”), in cash, without interest and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Soleno Therapeutics, Inc."},{"label":"Consideration","value":"$53.00 per Soleno Share"},{"label":"Closing","value":"2026-05-18"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}